Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | DRD5 | P21918 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519861 | 0.93 | SMN1; SMN2 (0.38) | NPC1TSHRLMNANPSR1MAOA | |
| SCHEMBL4525993 | 0.92 | DRD1 (0.37) | DRD1DRD5NPC1TSHRLMNA | |
| SCHEMBL4517370 | 0.91 | GRM1 (0.37) | NPSR1POLBBRD9YTHDC1GRM1 | |
| SCHEMBL4513062 | 0.89 | DRD1 (0.36) | DRD1DRD5NPC1TSHRLMNA | |
| SCHEMBL4520494 | 0.89 | MAOB (0.38) | DRD1DRD5TSHRLMNAXBP1 | |
| SCHEMBL4519245 | 0.89 | TP53 (0.37) | LMNAHTTNPSR1POLBBRD9 | |
| SCHEMBL4523638 | 0.88 | GSR (0.41) | DRD1DRD5NPSR1BRD9GSR | |
| SCHEMBL4529686 | 0.88 | DRD1 (0.37) | DRD1DRD5TSHRLMNAXBP1 | |
| SCHEMBL4529233 | 0.87 | DRD1 (0.40) | DRD1DRD5TSHRLMNAPOLB | |
| SCHEMBL4525444 | 0.86 | GSR (0.41) | DRD1DRD5TSHRLMNAXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | DRD1 333/4885DRD5 695/4885NPC1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.